Please assess the completion status of the following clinical trial:

Trial Title: Switching Study From Warfarin to Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 45 years of age;~* Normal body weight: BMI (body mass index) between 18 and 29 kg/m2;~* Pharmacogenetics: subjects who are homozygous for the wildtype allele 2C9\*1 and who are carriers of the C-allele at positions 6484 and 7566 of the VKORC1 (vitamin K epoxide reductase) gene, respectively~Exclusion Criteria:~* Relevant deviation from the normal range in the clinical examination;~* Relevant deviation from the normal range in clinical chemistry, hematology or urinalysis;~* Resting heart rate in the awake subject below 45 BPM (beats per minute) or above 90 BPM;~* Systolic blood pressure below 100 mmHg or above 140 mmHg; and Diastolic blood pressure above 85 mmHg;~* Relevant pathological changes in the ECG (electrocardiogram) such as a second or third-degree AV block, prolongation of the QRS (QRS complex in ECG) complex over 120 msec or of the QT / QTc-interval over 450 msec (QT interval in ECG, QTc interval corrected for heart rate);~* Subject is tested to be HIV-1/2Ab, p24Ag, HbsAg or HCV-Ab positive;~* Known coagulation disorders (e.g. von Willebrand's disease, haemophiliac);~* Known disorders with increased bleeding risks (e.g. periodontosis, hemorrhoids, acute gastritis, peptic ulcer);~* Known sensitivity to common causes of bleeding (e.g. nasal);~* Recent or planned surgical or diagnostic procedures at the central nervous system (CNS) or eye;~* Subjects with hyperlipidemia (Coumadin / warfarin warning)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
- Warfarin followed by Placebo (Type: PLACEBO_COMPARATOR): Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
- Rivaroxaban (Xarelto, BAY59-7939) (Type: ACTIVE_COMPARATOR): Days 0 to 3: 20 mg rivaroxaban once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).